AAPS PharmSciTech

, Volume 5, Issue 3, pp 90–99 | Cite as

In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil processes

  • Santos B. Murty
  • Qui Wei
  • B. C. Thanoo
  • Patrick P. DeLuca
Article

Abstract

The purpose of the present study was to characterize the in vivo release kinetics of octreotide acetate from microsphere formulations designed to minimize peptide acylation and improve drug stability. Microspheres were prepared by a conventional oil/wate (o/w) method or an experimental oil/oil (o/o) dispersion technique. The dosage forms were administered subcutaneously to a rat animal model, and serum samples were analyzed by radioimmunoassay over a 2-month period. An averaged kinetic profile from each treatment group, as a result, was treated with fractional differential equations. The results indicated that poly(l-lactide) microspheres prepared by the o/o dispersion technique provided lower area under the curve (AUC) values during the initial diffusion-controlled release phase, 7.79 ng×d/mL, versus 75.8 ng/sxd/mL for the o/w batch. During the subsequent erosion-controlled release phase, on the other hand, the o/o technique yielded higher AUC values, 123 ng×d/mL, versus 42.2 ng×d/mL for the o/w batch. The differences observed between the 2 techniques were attributed to the site of drug incorporation during the manufacturing process, given that microspheres contain both porous hydrophilic channels and dense hydrophobic matrix regions. An o/o dispersion technique was therefore expected to produce microspheres with lower incorporation in the aqueous channels, which are responsible for diffusion-mediated drug release.

Keywords

in vivo modeling octreotide acetate PLA microspheres PLGA microspheres radioimmunoassay 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Murty SB, Goodman J, Thanoo BC, DeLuca PP. Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions.AAPS PharmSciTech. 2003;4:E50.CrossRefGoogle Scholar
  2. 2.
    De Weck AL. Immunological effects of aspirin anhydride, a contaminant of commercial acetylsalicylic acid preparations.Int Arch Allergy Appl Immunol. 1971;41:393–418.Google Scholar
  3. 3.
    Jeyanthi R, Thanoo BC, Mehta RC, DeLuca PP. Effect of solvent removal technique on the matrix characteristics of polylactide/glycolide microspheres for peptide delivery.J Control Release. 1996;38:235–244.CrossRefGoogle Scholar
  4. 4.
    Jeyanthi R, Mehta RC, Thanoo BC, DeLuca PP. Effect of processing parameters on the properties of peptide-containing PLGA microspheres.J Microencapsul. 1997;14:163–174.CrossRefGoogle Scholar
  5. 5.
    Kostanski JW, Thanoo BC, DeLuca PP. Preparation, characterization, and in vitro evaluation of 1- and 4-month controlled release orntide PLA and PLGA microspheres.Pharm Dev Technol. 2000;5:585–596.CrossRefGoogle Scholar
  6. 6.
    Herrman J, Bodmeier R. Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods.Eur J Pharm Biopharm. 1998;45:75–82.CrossRefGoogle Scholar
  7. 7.
    Lai MC, Hageman MJ, Schowen RL, Borchardt RT, Topp EM. Chemical stability of peptides in polymers. 1. Effect of water on peptide deamidation in poly(vinyl alcohol) and poly(vinyl pyrrolidone) matrixes.J Pharm Sci. 1999;88:1073–1080.CrossRefGoogle Scholar
  8. 8.
    Lai MC, Hageman MJ, Schowen RL, Borchardt RT, Laird BB, Topp EM. Chemical stability of peptides in polymers. 2. Discriminating between solvent and plasticizing effects of water on peptide deamidation in poly(vinylpyrrolidone).J Pharm Sci. 1999;88:1081–1089.CrossRefGoogle Scholar
  9. 9.
    Hausberger AG, DeLuca PP. Characterization of biodegradable poly(D,L-lactide-co-glycolide) polymers and microspheres.J Pharm Biomed Anal. 1995;13:747–760.CrossRefGoogle Scholar
  10. 10.
    Comets E, Mentre F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits.J Pharm Sci. 2000;89:1123–1133.CrossRefGoogle Scholar
  11. 11.
    Murata K, Noda K, Kohno K, Samejima M. Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models.J Pharm Sci. 1987;76:109–113.CrossRefGoogle Scholar
  12. 12.
    Hwang SS, Bayne W, Theeuwes F.In vivo evaluation of controlled-release products.J Pharm Sci. 1993;82:1145–1150.CrossRefGoogle Scholar
  13. 13.
    Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats.Drug Metab Dispos. 1989;17:699–703.Google Scholar
  14. 14.
    Mason-Garcia M, Vaccarella M, Horvath J, et al. Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.Proc Natl Acad Sci U S A. 1988;85:5688–5692.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2004

Authors and Affiliations

  • Santos B. Murty
    • 1
  • Qui Wei
    • 2
  • B. C. Thanoo
    • 3
  • Patrick P. DeLuca
    • 2
  1. 1.Murty Pharmaceuticals IncLexington
  2. 2.Faculty of Pharmaceutical SciencesUniversity of Kentucky College of PharmacyLexington
  3. 3.Oakwood Laboratories LLCOakwood

Personalised recommendations